15:32 , May 21, 2019 |  BC Extra  |  Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
14:21 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

WWP1 inhibitor for MYC-driven prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer In vitro and mouse studies identified a WWP1 inhibitor that could help treat MYC-driven prostate cancer. In a mouse model of MYC-overexpressing prostate cancer, systemic knockout of WWP1 or...
14:20 , May 14, 2019 |  BC Innovations  |  Distillery Therapeutics

GSK3A inhibition restores asparaginase sensitivity in resistant ALL, AML

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting GSK3A could help treat asparaginase-resistant T cell and B cell ALL and AML. In a T...
14:19 , May 14, 2019 |  BC Innovations  |  Distillery Techniques

A mouse model to screen therapies for Williams syndrome

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: Transgenics and knockouts GTF2I-deficient mice could be used to screen therapies for Williams syndrome, which is caused by gene deletions on chromosome 7 that lead to learning and cardiovascular problems....
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
19:24 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

AGTR1 inhibitor nanoconjugate boosts chemo, immunotherapies in cancers

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer; breast cancer Mouse studies suggest a nanoconjugate based on the generic ATGR1 inhibitor valsartan could enhanced the efficacy of chemotherapies and checkpoint inhibitors in pancreatic and metastatic breast cancers....
19:20 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

CX3CL1 gene therapy for retinitis pigmentosa

DISEASE CATEGORY: Ophthalmic disease INDICATION: Retinitis Mouse studies suggest CX3CL1 gene therapy could help treat retinitis pigmentosa. In three mouse models of retinitis pigmentosa, CX3CL1 encoded in an adeno-associated viral (AAV) serotype 8 (AAV8) vector...
01:42 , May 4, 2019 |  BioCentury  |  Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
01:39 , May 4, 2019 |  BioCentury  |  Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
20:39 , May 2, 2019 |  BC Innovations  |  Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

SAB’s platform for producing human polyclonal antibodies directly in cows and goats avoids the limitations of other methods that start from animal or donor-derived antibodies. Therapeutic mAbs and bi- and tri-specific antibodies target no more...